Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Subjects
An Open-label, Single Sequence Crossover, Drug Interaction Study to Investigate the Effect of Linerixibat (GSK2330672) on Plasma Concentrations of Obeticholic Acid and Conjugates in Healthy Participants
Sponsor: GlaxoSmithKline
Listed as NCT04053023, this PHASE1 trial focuses on Cholestasis and remains completed. Sponsored by GlaxoSmithKline, it has been updated 8 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE1
-
Jan 2020 — Aug 2020 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 3 earlier versions
-
Nov 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Oct 2019 — Nov 2019 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2019 — Oct 2019 [monthly]
Not Yet Recruiting PHASE1
First recorded
Aug 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .